Formulation and evaluation of swellable and floating gastroretentive ciprofloxacin hydrochloride tablets

AAPS PharmSciTech

Volumn 10, Issue 1, 2009, Pages 220-226

  Arza, Ramji Anil Kumar ^a   Gonugunta, Chandra Sekhara Rao ^a   Veerareddy, Prabhakar Reddy ^a  

^a ST PETER'S INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Ciprofloxacin; Floating; Gastroretentive; In vivo studies; Swellable

Indexed keywords

BICARBONATE; CIFRAN OD; CIPROFLOXACIN; CROSCARMELLOSE SODIUM; CROSPOVIDONE; HYDROXYPROPYLMETHYLCELLULOSE; STARCH GLYCOLATE SODIUM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CARBOXYMETHYLCELLULOSE; DRUG DERIVATIVE; EXCIPIENT; METHYLCELLULOSE; POVIDONE; STARCH;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN EXPERIMENT; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION; CHEMICAL MODEL; CHEMISTRY; DRUG FORMULATION; EVALUATION; METABOLISM; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; RADIOGRAPHY; SOLUBILITY; STOMACH; STOMACH EMPTYING; TABLET;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; CARBOXYMETHYLCELLULOSE; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; DRUG COMPOUNDING; EXCIPIENTS; GASTRIC EMPTYING; HUMANS; METHYLCELLULOSE; MODELS, CHEMICAL; POVIDONE; SODIUM BICARBONATE; SOLUBILITY; STARCH; STOMACH; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 67549083691     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9200-y     Document Type: Article

References (27)

1. S. Baumgartner, J. Kristl, F. Vrecer, P. Vodopivec, and B. Zorko. Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int. J. Pharm. 195:125-135 (2000).
2. B. N. Singh, and K. H. Kim. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J. Control. Rel. 63: 235-259 (2000).
3. A. Streubel, J. Siepmann, and R. Bodmeier. Floating matrix tablets based on low-density foam powder: Effects of formulation and processing parameters on drug release. Eur. J. Pharm. Sci. 181:37-45 (2003).
4. R. C. Mamajek, and E. S. Moyer, Drug-dispensing device and method. US Patent 4, 207, 890, 1980.
5. J. Urquhart, and F. Theeuwes, Drug delivery system comprising a reservoir containing a plurality of tiny pills. U.S. patent 4, 434, 153, February 28, 1984.
6. N. Saito, K. Konishi, F. Sato, M. Kato, H. Takeda, T. Sugiyama, and M. Asaka. Plural transformation-processes from spiral to coccoid Helicobacter pylori and its viability. J. Infect. 461:49-55 (2003).
7. K. Park, and J. R. Robinson. Bioadhesive polymers as platforms for oral-controlled drug delivery: Method to study bioadhesion. Int. J. Pharm. 192:107-127 (1984).
8. Y. Kawashima, T. Niwa, H. Takeuchi, T. Hino, and Y. Itoh. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J. Pharm. Sci. 812:135-140 (1992).
9. G. M. Clarke, J. M. Newton, and M. D. Short. Gastrointestinal transit of pellets of differing size and density. Int. J. Pharm. 1001-3:81-92 (1993).
10. E. A. Klausner, E. Lavy, M. Friedman, and A. Hoffman. Expandable gastroretentive dosage forms. J. Control. Release. 902:143-162 (2003).
11. J. Chen, W. E. Blevins, H. Park, and K. Park. Gastric retention properties of superporous hydrogel composites. J. Control. Release. 641-3:39-51 (2000).
12. J. Chen, and K. Park. Synthesis and characterization of superporous hydrogel composites. J. Control. Release. 651-2:73-82 (2000).
13. R. Ito, Y. Machida, T. Sannan, and T. Nagai. Magnetic granules: A novel system for specific drug delivery to esophageal mucosa in oral administration. Int. J. Pharm. 611-2:109-117 (1990).
14. V. S. Chitnis, V. S. Malshe, and J. K. Lalla. Bioadhesive polymer synthesis, evaluation and application in controlled release tablets. Drug Dev. Ind. Pharm. 176:879-892 (1991).
15. M. Efentakis, A. Koutlis, and M. Vlachou. Development and evaluation of oral multiple-unit and single-unit hydrophilic controlled-release systems. AAPS PharmSciTech. 14:34 (2000).
16. A. H. El-Kamel, M. S. Sokar, S. S. Al Gamal, and V. F. Naggar. Preparation and evaluation of ketoprofen floating oral delivery system. Int. J. Pharm. 220:13-21 (2001).
17. A. Srinath, and J. K. Pandit. Multiple-unit floating alginate system: effect of additives on ciprofloxacin release. Drug Deliv. 15 7:471-476 (2008).
18. S. K. Sahoo, S. Mohapatra, S. K Dhal, B. C. Behera, and B. B. Barik. Formulation of floating microspheres of ciprofloxacin hydrochloride by crosslinking technique. Indian Pharm. 586:65-68 (2007).
19. J. Varshosaz, N. Tavakoli, and F. Roozbahani. Formulation and in vitro characterization of ciprofloxacin floating and bioadhesive extended-release tablets. Drug Deliv. 13:277-285 (2006).
20. Bayer. Cipro® XR (Ciprofloxacin extended-release tablets) prescribing information. West Haven, CT, December 2005.
21. Esprit Pharma. ProQuin® XR (Ciprofloxacin hydrochloride) extended-release tablets prescribing information. East Brunswick, NJ, October 2005.
22. V. Agarwal, and B. Mishra. Design, development and biopharmaceutical properties of buccoadhesive compacts of pentazocine. Drug Dev. Ind. Pharm. 256:701-709 (1999).
23. F. A. Mohammed, and H. Khedr. Preparation and in vitro/in vivo evaluation of the buccal bioadhesive properties of slow-release tablets containing miconazole nitrate. Drug Dev. Ind. Pharm. 293:321-337 (2003).
24. M. Chanvanpatil, P. Jain, S. chaudhari, R. Shear, and P. Vavia. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int. J. Pharm. 316:86-92 (2006).
25. V. S. Gerogiannis, D. M. Rekkas, P. P. Dallas, and N. H. Choulis. Floating and swelling characteristics of various excipients used in controlled release technology. Drug Dev. Ind. Pharm. 199:1061-1081 (1993).
26. Y. Machida, K. Inouyå T. Tokumura, M. Iwata, and T. Nagai. Preparation and evaluation of intragastric buoyant preparations. Drug Des. Deliv. 4:155-161 (1989).
27. V. Iannucelli, G. Coppi, R. Sansone, and G. Ferolla. Air compartment multiple-unit system for prolonged gastric residence. Part II. In vivo evaluation. Int. J. Pharm. 174: 55-62 (1998).